All IndicationsOncologyApprovedApprovedPhase 2Phase 2Phase 2Phase 2
🎗️
Cancer
8
Companies
8
Drug Programs
0
Phase 3
0
Upcoming PDUFAs
Competitors
SNY
Sanofi
Sarclisa Escena
CELC
Celcuity
Revtorpyk
KRYS
Krystal Biotech, Inc.
Opdualag
NVS
Novartis AG
GSK2110183 (afuresertib)
ACTU
ACTUATE THERAPEUTICS, INC.
9-ING-41
ABUS
Arbutus Biopharma Corp
TKM-080301
SCLP.L
Scancell
cancer drug
TRAX
Trethera
TRE-515
| Company | Drug | Phase | Designations | Timeline | Trial ID |
|---|---|---|---|---|---|
| SNY Sanofi | Sarclisa Escena | Approved | — | — | — |
| CELC Celcuity | Revtorpyk | Approved | — | — | — |
| KRYS Krystal Biotech, Inc. | Opdualag | Phase 2 | — | — | — |
| NVS Novartis AG | GSK2110183 (afuresertib) | Phase 2 | — | — | — |
| ACTU ACTUATE THERAPEUTICS, INC. | 9-ING-41 | Phase 2 | — | — | — |
| ABUS Arbutus Biopharma Corp | TKM-080301 | Phase 2 | — | — | — |
| SCLP.L Scancell | cancer drug | — | — | — | — |
| TRAX Trethera | TRE-515 | — | — | — | — |
Development Stage Distribution
Unknown
2
Approved
2
Phase 2
4
PDUFA Timeline
No upcoming PDUFA dates for this indication.
Not financial advice
Signals are probabilistic and based on historical data — past performance doesn't guarantee future results. Do your own research.